Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
arrhythmia
atrial fibrillation
heart failure
meta-analysis
sodium-glucose co-transporter type 2 inhibitors
type 2 diabetes mellitus
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
03
2022
accepted:
04
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Arrhythmic events such as atrial fibrillation (AF) are tightly associated with an increased risk of heart failure (HF). Previous studies have shown inconsistent results regarding the association between sodium-glucose co-transporter 2 inhibitors (SGLT2i) and the risk of arrhythmia. The purpose of this study was to investigate the association of SGLT2i treatment with arrhythmia outcomes in clinical trials of patients with HF. We searched Embase, PubMed, Web of Science, Medline, The Cochrane Library, and JAMA databases to identify appropriate randomized controlled trials (RCTs) of SGLT2i interventions. Endpoint outcomes included AF, atrial flutter (AFL), AF/AFL, ventricular fibrillation (VF), ventricular tachycardia (VT), VF/VT, and bradycardia. A random-effects model was used for the meta-analysis of all outcomes. The risk of bias and quality of evidence was assessed by using the Cochrane tool and assessment framework. Out of 1,725 citations, 9 trials were included in this study, with follow-up from 4 weeks to 52 weeks for 10,344 participants (mean age 68.27 years; 69.62% of participants were men). Compared with placebo, SGLT2i reduced the incidence of AF by 37% [ratio risk (RR) 0.63; 95% confidence interval (CI) 0.45-0.87; SGLT2i can reduce the risk of cardiac arrhythmias, particularly the AF. Our study provides strong evidence for recommending the use of SGLT2i in patients with HF. PROSPERO, identifier: CRD42022296696.
Identifiants
pubmed: 35665272
doi: 10.3389/fcvm.2022.902923
pmc: PMC9157597
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
902923Informations de copyright
Copyright © 2022 Yin, Zheng and Guo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Mol Sci. 2021 Jul 26;22(15):
pubmed: 34360742
J Cell Biochem. 2003 Oct 1;90(2):339-46
pubmed: 14505350
J Am Coll Cardiol. 2010 May 25;55(21):2330-42
pubmed: 20488304
Am J Physiol Heart Circ Physiol. 2013 Apr 15;304(8):H1060-76
pubmed: 23396451
Eur Heart J. 2021 Dec 21;42(48):4947-4960
pubmed: 34293101
Basic Res Cardiol. 2011 Mar;106(2):263-72
pubmed: 21174213
Cardiovasc Drugs Ther. 2019 Feb;33(1):87-95
pubmed: 30675708
Front Aging. 2021;2:
pubmed: 35309549
ESC Heart Fail. 2020 Sep 18;:
pubmed: 32946200
Eur Heart J. 2021 Sep 21;42(36):3727-3738
pubmed: 34448003
Eur J Heart Fail. 2019 May;21(5):665-675
pubmed: 30895697
Life Sci. 2021 Jul 1;276:119440
pubmed: 33781832
Circulation. 2016 Feb 2;133(5):484-92
pubmed: 26746177
Diabetes Ther. 2010 Dec;1(2):57-92
pubmed: 22127746
N Engl J Med. 2016 Mar 17;374(11):1094
pubmed: 26981940
Circ Res. 2016 Jun 10;118(12):1960-91
pubmed: 27126807
Cardiovasc Diabetol. 2020 Aug 26;19(1):130
pubmed: 32847602
Circulation. 2020 Oct 27;142(17):e265-e286
pubmed: 32981345
Heart Fail Rev. 2021 May;26(3):603-622
pubmed: 33150520
N Engl J Med. 2017 Nov 23;377(21):2099
pubmed: 29166232
Front Pharmacol. 2022 Mar 09;13:856386
pubmed: 35370704
Circulation. 2020 Apr 14;141(15):1227-1234
pubmed: 31983236
Eur Heart J. 2021 Feb 11;42(6):700-710
pubmed: 33351892
Heart. 2022 Mar;108(6):422-428
pubmed: 34088767
Circulation. 2021 Jan 26;143(4):337-349
pubmed: 33175585
Diabetes Care. 2016 Jul;39(7):1115-22
pubmed: 27289124
J Am Coll Cardiol. 2021 Mar 23;77(11):1381-1392
pubmed: 33736819
Diabetes Obes Metab. 2021 Jan;23(1):276-280
pubmed: 33001548
Pflugers Arch. 2015 Sep;467(9):1881-98
pubmed: 25304002
JACC Heart Fail. 2019 Jun;7(6):447-456
pubmed: 31146871
Cardiovasc Diabetol. 2021 May 7;20(1):100
pubmed: 33962654
Eur J Heart Fail. 2020 Apr;22(4):713-722
pubmed: 31912605
Diabetologia. 2018 Mar;61(3):722-726
pubmed: 29197997
Heart Rhythm. 2021 Jul;18(7):1098-1105
pubmed: 33757845
Trends Cardiovasc Med. 2017 Feb;27(2):144-151
pubmed: 27612553
PLoS One. 2015 Jun 29;10(6):e0130605
pubmed: 26121582
Cardiovasc Diabetol. 2021 Feb 11;20(1):39
pubmed: 33573667
Biochem Pharmacol. 2021 Oct;192:114674
pubmed: 34252408
Card Fail Rev. 2020 Nov 13;6:e31
pubmed: 33294215
Physiol Rev. 2011 Apr;91(2):733-94
pubmed: 21527736
Drug Discov Today Dis Mech. 2010 Summer;7(2):e95-e102
pubmed: 21278905
Drugs. 2021 Aug;81(12):1381-1395
pubmed: 34297330
Drug Des Devel Ther. 2017 Oct 03;11:2905-2919
pubmed: 29042751
Cardiovasc Diabetol. 2017 Jan 13;16(1):9
pubmed: 28086951
Diabetologia. 2017 Mar;60(3):568-573
pubmed: 27752710
Eur J Heart Fail. 2022 Mar;24(3):513-525
pubmed: 34766424
N Engl J Med. 2021 Jan 14;384(2):117-128
pubmed: 33200892
J Am Heart Assoc. 2021 Mar 16;10(6):e018298
pubmed: 33719499
Circ J. 2014;78(2):300-6
pubmed: 24334638
Eur J Prev Cardiol. 2018 Mar;25(5):495-502
pubmed: 29372664
Cardiovasc Diabetol. 2020 Jan 7;19(1):5
pubmed: 31910841
Cardiovasc Diabetol. 2019 Nov 28;18(1):165
pubmed: 31779619
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
J Am Heart Assoc. 2021 Jan 19;10(2):e017483
pubmed: 33399004
Am J Pathol. 1977 Dec;89(3):575-604
pubmed: 145805
Cardiovasc Res. 2018 Jan 1;114(1):12-18
pubmed: 29016751
J Endocrinol. 2018 Feb;236(2):69-84
pubmed: 29142025
ESC Heart Fail. 2021 Aug;8(4):2580-2590
pubmed: 33960149
JCI Insight. 2021 Oct 28;6(23):
pubmed: 34710060
Circulation. 2016 Feb 23;133(8):698-705
pubmed: 26819376
J Biol Chem. 2003 Sep 19;278(38):36027-31
pubmed: 12840017
Circulation. 2019 Oct 29;140(18):1463-1476
pubmed: 31524498
J Am Coll Cardiol. 2010 May 25;55(21):2343-5
pubmed: 20488305